13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001940272
Total reported value
$2.2B
$2.2B
203 檔
17.5%
At the close of Q3 2025, ADAR1 Capital Management, LLC disclosed equity holdings valued at approximately $2.2B, spread across 203 reported holdings.
In Q3 2025, ADAR1 Capital Management, LLC displayed an active expansion posture, initiating 64 new positions and adding to 54 existing holdings, outstripping position reductions.
Showing top 200 holdings (of 203 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | Stock-Other | 10.77% | +1.85% | -56.02% | |
| 2 | KROS | Keros Therapeutics Inc | Stock-Other | 8.01% | +0.06% | — | |
| 3 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 6.27% | +2.36% | +58.56% | |
| 4 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 6.17% | -0.78% | +4.34% | |
| 5 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 4.76% | -0.25% | +72.48% | |
| 6 | BOXX | Alpha Architect 1-3 Mnth Box | ETF-Other | 3.61% | -0.50% | — | |
| 7 | IMVT | Immunovant Inc | Stock-Other | 3.39% | +0.19% | +318.97% | |
| 8 | ETNBGBP | 89bio Inc | Stock-Other | 2.92% | — | +141.23% | |
| 9 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 2.77% | +1.35% | +2.16% | |
| 10 | CYTK | Cytokinetics Inc | Stock-Healthcare | 2.68% | -0.66% | -10.86% | |
| 11 | SEPN | Septerna Inc | Stock-Other | 2.08% | -0.10% | +38.86% | |
| 12 | QURE | uniQure N.V. | Stock-Other | 1.83% | +0.51% | — | |
| 13 | PRTA | Prothena Corporation plc | Stock-Other | 1.35% | -0.20% | -56.47% | |
| 14 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.33% | +0.19% | +5.30% | |
| 15 | ABUS | Arbutus Biopharma CORP | Stock-Other | 1.24% | -0.55% | +2.74% | |
| 16 | RAPT | Rapt Therapeutics Inc | Stock-Other | 1.23% | — | -35.17% | |
| 17 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.21% | -0.36% | +31.28% | |
| 18 | BIL | Ss Spdr Bb 1-3m T-bill ETF | ETF-Gov Bonds | 1.17% | -0.16% | — | |
| 19 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 1.11% | -0.38% | -28.12% | |
| 20 | BIOA | Bioage Labs Inc | Stock-Other | 1.04% | -0.14% | EXIT | |
| 21 | MNPR | Monopar Therapeutics Inc | Stock-Other | 1.00% | +0.07% | +28.75% | |
| 22 | YCY-UN | AA Mission Acquisition Corp. II | Stock-Other | 0.97% | — | +70.04% | |
| 23 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.97% | -0.35% | +367.52% | |
| 24 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.96% | -0.17% | +955.73% | |
| 25 | CGON | Cg Oncology Inc | Stock-Other | 0.94% | -0.35% | -52.43% | |
| 26 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.87% | +0.17% | -5.79% | |
| 27 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.83% | +0.08% | +367.12% | |
| 28 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.82% | -0.11% | -9.86% | |
| 29 | JANX | Janux Therapeutics Inc | Stock-Other | 0.81% | +0.06% | +7.35% | |
| 30 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.80% | +0.04% | +2.45% | |
| 31 | IVVD | Invivyd Inc | Stock-Other | 0.76% | -0.14% | — | |
| 32 | ✓ | Stock-Other | 0.75% | — | — | ||
| 33 | EQ | Equillium Inc | Stock-Other | 0.75% | +0.11% | — | |
| 34 | ✓ | Stock-Other | 0.74% | +0.02% | — | ||
| 35 | PCVX | Vaxcyte Inc | Stock-Other | 0.72% | -0.50% | +117.34% | |
| 36 | RZLT | Rezolute Inc | Stock-Other | 0.72% | — | -17.52% | |
| 37 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.71% | -0.32% | -27.13% | |
| 38 | ASND | Ascendis Pharma A/S | Stock-Other | 0.68% | -0.34% | EXIT | |
| 39 | SVRA | Savara Inc | Stock-Other | 0.67% | -0.07% | -44.78% | |
| 40 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.63% | +0.26% | +31.85% | |
| 41 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.61% | -0.02% | +3.73% | |
| 42 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 0.55% | — | — | |
| 43 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.52% | — | +80.84% | |
| 44 | ✓ | Stock-Other | 0.51% | -0.06% | — | ||
| 45 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 0.51% | -0.05% | -22.57% | |
| 46 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.47% | -0.39% | +9.21% | |
| 47 | ATAI | AtaiBeckley Inc. | Stock-Other | 0.45% | — | — | |
| 48 | UTHR | United Therapeutics CORP | Stock-Healthcare | 0.44% | — | — | |
| 49 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.43% | +0.58% | +159.42% | |
| 50 | BBIO 2.25 02-01-29Bond | Bridgebio Pharma Inc | Bond | 0.42% | -0.06% | -99.00% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ABVX | Abivax Sa-adr | +8.2% | -56.02% | Trim |
| 2 | KROS | Keros Therapeutics Inc | +5.2% | — | Add |
| 3 | ETNBGBP | 89bio Inc | +1.8% | +141.23% | Add |
| 4 | SEPN | Septerna Inc | +1.3% | +38.86% | Add |
| 5 | CTMX | Cytomx Therapeutics Inc | +1.2% | +31.28% | Add |
| 6 | LXEO | Lexeo Therapeutics Inc | +0.9% | +955.73% | Add |
| 7 | REGN | Regeneron Pharmaceuticals | +0.7% | +367.12% | Add |
| 8 | CRNX | Crinetics Pharmaceuticals In | +0.6% | +367.52% | Add |
| 9 | ASND | Ascendis Pharma A/S | +0.6% | +2492.37% | Add |
| 10 | PCVX | Vaxcyte Inc | +0.6% | +117.34% | Add |
| 11 | TSHA | Taysha Gene Therapies Inc | +0.6% | -5.79% | Add |
| 12 | BIOA | Bioage Labs Inc | +0.4% | -2.95% | Add |
| 13 | IMVT | Immunovant Inc | +0.3% | +318.97% | Add |
| 14 | MNPR | Monopar Therapeutics Inc | +0.3% | +28.75% | Add |
| 15 | ✓ | Establishment Labs Holdings In | +0.3% | +262.75% | Add |
| 16 | VRNA | Verona Pharma PLC - Adr | +0.3% | +80.84% | Add |
| 17 | CLDX | Celldex Therapeutics Inc | +0.2% | +90.45% | Add |
| 18 | VKTX | Viking Therapeutics Inc | +0.2% | +159.42% | Add |
| 19 | AMLX | Amylyx Pharmaceuticals Inc | +0.1% | -28.12% | Trim |
| 20 | BIIB | Biogen Inc | +0.1% | +252.94% | Add |
| 21 | RZLT | Rezolute Inc | +0.1% | -17.52% | Trim |
| 22 | MDGL | Madrigal Pharmaceuticals Inc | +0.1% | +364.42% | Add |
| 23 | RYTM | Rhythm Pharmaceuticals Inc | +0.1% | +9.21% | Add |
| 24 | CDTX | Cidara Therapeutics Inc | +0.1% | — | Add |
| 25 | ABOS | Acumen Pharmaceuticals Inc | +0.1% | -2.73% | Add |
| 26 | FULC | Fulcrum Therapeutics Inc | +0.1% | +680.92% | Trim |
| 27 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.1% | +32.98% | Add |
| 28 | OABI | Omniab Inc | +0.1% | +234.44% | Add |
| 29 | QNCX | Quince Therapeutics, Inc. | +0.1% | +442.14% | Add |
| 30 | ACLXGBX | Arcellx Inc | +0.1% | +125.50% | Add |
| 31 | MLTX | Moonlake Immunotherapeutics | +0.1% | +391.04% | Add |
| 32 | WVE | Wave Life Sciences Ltd. | +0.1% | +3.70% | Add |
| 33 | ARWR | Arrowhead Pharmaceuticals In | 0% | -9.78% | Trim |
| 34 | DNLI | Denali Therapeutics Inc | 0% | +44.24% | Add |
| 35 | AVTX | Avalo Therapeutics Inc | 0% | -69.07% | Add |
| 36 | ABUS | Arbutus Biopharma CORP | 0% | +2.74% | Add |
| 37 | GOSS | Gossamer Bio Inc | 0% | +17.78% | Add |
| 38 | KURA | Kura Oncology Inc | 0% | +60.35% | Add |
| 39 | VRDN | Viridian Therapeutics Inc | 0% | -40.38% | Add |
| 40 | BNTX | Biontech Se-adr | 0% | — | Add |
| 41 | DYN | Dyne Therapeutics Inc | 0% | +33.90% | Add |
| 42 | SYRE | Spyre Therapeutics Inc | 0% | — | Add |
| 43 | AGIO | Agios Pharmaceuticals Inc | 0% | +3.06% | Add |
| 44 | NGNE | Neurogene Inc | 0% | +3.40% | Add |
| 45 | PHAT | Phathom Pharmaceuticals Inc | 0% | -32.36% | Trim |
| 46 | LLY | Eli Lilly & Co | 0% | +100.00% | Add |
| 47 | EWTX | Edgewise Therapeutics Inc | 0% | — | Add |
| 48 | GERN | Geron CORP | 0% | +3.40% | Add |
| 49 | SVRA | Savara Inc | 0% | -44.78% | Add |
| 50 | BHVN | Biohaven Ltd. | 0% | -13.95% | Add |
According to official SEC Form 13F filings, ADAR1 Capital Management, LLC reported a total U.S. public equity portfolio value of $2.2B across 203 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ABVX, KROS, SPY) accounted for 17.5% of total reported equity market value during Q3 2025.
Top New Position Initiated
SPY
市值: $66.7M
Top Position Liquidated / Trimmed
SWTXUSD
前期市值: $9.8M
During Q3 2025, ADAR1 Capital Management, LLC's top holdings by market value included ABVX (10.8%)、KROS (8.0%)、SPY (6.3%). The largest single position, ABVX, represented 10.8% of total portfolio value.
In Q3 2025, ADAR1 Capital Management, LLC made 197 total portfolio adjustments, initiating 64 new buys, adding to 54 positions, trimming 40 holdings, and fully liquidating 39 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.